SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
India · Delayed Price · Currency is INR 368.00
+0.50 (0.14%)
Feb 18, 2026, 12:00 PM IST
SMS Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 8,971 | 7,827 | 7,093 | 5,221 | 5,199 | 5,632 |
| 8,971 | 7,827 | 7,093 | 5,221 | 5,199 | 5,632 | |
Revenue Growth (YoY) | 14.96% | 10.36% | 35.86% | 0.42% | -7.69% | 35.93% |
Cost of Revenue | 6,058 | 5,241 | 4,983 | 3,900 | 3,309 | 3,797 |
Gross Profit | 2,913 | 2,587 | 2,109 | 1,321 | 1,890 | 1,835 |
Selling, General & Admin | 878.88 | 828.53 | 658.08 | 547.63 | 515.16 | 414.94 |
Other Operating Expenses | 309.79 | 365.67 | 281.41 | 224.85 | 222.38 | 202.34 |
Operating Expenses | 1,573 | 1,538 | 1,255 | 1,094 | 1,059 | 840.09 |
Operating Income | 1,340 | 1,049 | 854.71 | 226.98 | 830.73 | 994.62 |
Interest Expense | -217.58 | -174.35 | -226.18 | -209.94 | -181.57 | -102.54 |
Interest & Investment Income | 6.87 | 6.87 | 7.58 | 7.75 | 5.6 | 3.14 |
Earnings From Equity Investments | 24.74 | 17.37 | 6.26 | -109.43 | -56.61 | 15.62 |
Currency Exchange Gain (Loss) | 50.78 | 50.78 | 28.98 | 39.05 | 25.8 | 5.71 |
Other Non Operating Income (Expenses) | 0.61 | -9.18 | -4.39 | -9.8 | 4.47 | 10.34 |
EBT Excluding Unusual Items | 1,205 | 940.54 | 666.96 | -55.4 | 628.42 | 926.9 |
Gain (Loss) on Sale of Assets | 0.21 | 0.21 | 0.37 | -0.54 | -0.04 | -0.08 |
Pretax Income | 1,206 | 940.74 | 667.33 | -55.94 | 628.38 | 926.82 |
Income Tax Expense | 309.79 | 249.39 | 169.07 | 14.65 | 6.18 | 301.55 |
Earnings From Continuing Operations | 895.9 | 691.35 | 498.26 | -70.59 | 622.2 | 625.27 |
Minority Interest in Earnings | 0.01 | 0.01 | - | - | - | - |
Net Income | 895.91 | 691.36 | 498.26 | -70.59 | 622.2 | 625.27 |
Net Income to Common | 895.91 | 691.36 | 498.26 | -70.59 | 622.2 | 625.27 |
Net Income Growth | 35.54% | 38.75% | - | - | -0.49% | 98.04% |
Shares Outstanding (Basic) | 93 | 89 | 85 | 85 | 85 | 85 |
Shares Outstanding (Diluted) | 93 | 89 | 85 | 85 | 85 | 85 |
Shares Change (YoY) | 10.24% | 4.72% | - | - | - | - |
EPS (Basic) | 9.61 | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
EPS (Diluted) | 9.61 | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
EPS Growth | 22.95% | 32.49% | - | - | -0.49% | 98.04% |
Free Cash Flow | - | -416.71 | -20.35 | -74.71 | 178.12 | -612.96 |
Free Cash Flow Per Share | - | -4.70 | -0.24 | -0.88 | 2.10 | -7.24 |
Dividend Per Share | - | 0.400 | 0.400 | 0.300 | 0.300 | 0.300 |
Dividend Growth | - | - | 33.33% | - | - | 20.00% |
Gross Margin | 32.47% | 33.05% | 29.74% | 25.30% | 36.35% | 32.58% |
Operating Margin | 14.94% | 13.40% | 12.05% | 4.35% | 15.98% | 17.66% |
Profit Margin | 9.99% | 8.83% | 7.03% | -1.35% | 11.97% | 11.10% |
Free Cash Flow Margin | - | -5.32% | -0.29% | -1.43% | 3.43% | -10.88% |
EBITDA | 1,700 | 1,387 | 1,163 | 541.39 | 1,142 | 1,207 |
EBITDA Margin | 18.95% | 17.72% | 16.40% | 10.37% | 21.97% | 21.43% |
D&A For EBITDA | 360.09 | 338.06 | 308.68 | 314.41 | 311.36 | 212.32 |
EBIT | 1,340 | 1,049 | 854.71 | 226.98 | 830.73 | 994.62 |
EBIT Margin | 14.94% | 13.40% | 12.05% | 4.35% | 15.98% | 17.66% |
Effective Tax Rate | 25.69% | 26.51% | 25.34% | - | 0.98% | 32.54% |
Revenue as Reported | 9,043 | 7,890 | 7,137 | 5,270 | 5,251 | 5,666 |
Advertising Expenses | - | 23.52 | 15.86 | 8.59 | 4 | 2.18 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.